- Trials with a EudraCT protocol (1,464)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,464 result(s) found for: Open biopsy.
Displaying page 1 of 74.
EudraCT Number: 2015-003740-39 | Sponsor Protocol Number: URO-CHUAC-BPSat-001. | Start Date*: 2016-04-12 | |||||||||||
Sponsor Name:Jose Luis Ponce Díaz-Reixa | |||||||||||||
Full Title: Open randomized clinical trial to examine individual pain tolerance in the use of two anesthetic techniques to perform saturation prostate biopsy . | |||||||||||||
Medical condition: Prostate biopsy anesthesia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002564-27 | Sponsor Protocol Number: STH16037 | Start Date*: 2013-01-31 |
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | ||
Full Title: Pilot open study of testosterone replacement in non-alcoholic steatohepatitis | ||
Medical condition: Non alcoholic fatty liver disease (NAFLD) in men with low serum testosterone levels | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-018311-15 | Sponsor Protocol Number: GE-148-003 | Start Date*: 2010-05-21 |
Sponsor Name:GE Healthcare Limited | ||
Full Title: A Phase 2, Open-label Study to Assess the Uptake and Retention and Safety of GE 148 (18F) Injection in Subjects with Biopsy-proven Prostate Cancer who are Scheduled for Radical Prostatectomy | ||
Medical condition: Detection of abnormal amino acid transport using Positron Emission Tomography (PET) in malignancy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002073-56 | Sponsor Protocol Number: Aramchol-018 | Start Date*: 2020-01-06 | |||||||||||
Sponsor Name:Galmed Research and Development, Ltd. | |||||||||||||
Full Title: A Phase 3, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH) The ARMO... | |||||||||||||
Medical condition: Nonalcoholic Steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) BE (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002637-15 | Sponsor Protocol Number: APL2-C3G-204 | Start Date*: 2020-12-22 |
Sponsor Name:Apellis Pharmaceuticals, Inc. | ||
Full Title: AN OPEN-LABEL, RANDOMIZED, CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PEGCETACOPLAN IN THE TREATMENT OF POST-TRANSPLANT RECURRENCE OF C3G OR IC‑MPGN | ||
Medical condition: complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) AT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) FR (Completed) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001722-21 | Sponsor Protocol Number: D533AC00001 | Start Date*: 2022-03-08 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: MONETTE: A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance ... | ||||||||||||||||||
Medical condition: Unresectable or Advanced Melanoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000252-41 | Sponsor Protocol Number: PIPF-004 | Start Date*: 2006-06-29 | |||||||||||
Sponsor Name:InterMune, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo Controlled, Phase 3 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis | |||||||||||||
Medical condition: Idiopathic Pulmonary Fibrosis (IPF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001530-40 | Sponsor Protocol Number: HEC WST06 1276N/WST 2.24 | Start Date*: 2006-07-18 | |||||||||||
Sponsor Name:STEBA FRANCE | |||||||||||||
Full Title: Vascular targeted photodynamic therapy using WST09 for patients with untreated localised prostate cancer - Repeat procedure – Phase IIa, Single centre, open-label study. | |||||||||||||
Medical condition: Localised Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001762-42 | Sponsor Protocol Number: 4658-402 | Start Date*: 2020-04-03 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of a High Dose of Eteplirsen, Preceded by an Open-Label Dose Escalation, in Patients with Duchenne Muscular ... | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: IE (Completed) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) SE (Prematurely Ended) DE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) NO (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) SI (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003064-47 | Sponsor Protocol Number: CUDC-101-104 | Start Date*: 2012-12-11 | |||||||||||
Sponsor Name:Curis, Inc. | |||||||||||||
Full Title: A Phase 1 open-label study to investigate the pharmacodynamics, metabolomics and pharmacokinetics of CUDC-101 in subjects with HER2 positive invasive breast cancer. | |||||||||||||
Medical condition: HER2 positive breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003386-22 | Sponsor Protocol Number: PRX302-2-07 | Start Date*: 2015-01-19 |
Sponsor Name:Sophiris Bio Corp | ||
Full Title: A Single Centre, Open Label, Phase IIa Study, Evaluating the Safety and Tolerability of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically Signific... | ||
Medical condition: Prostate cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-000821-31 | Sponsor Protocol Number: 307969 | Start Date*: 2004-11-16 |
Sponsor Name:Schering AG | ||
Full Title: Multi-center, open, randomized, parallel group comparison of cycle control for seven cycles and endometrial safety in a subgroup for thirteen cycles of contraceptive patch SH P00331F (0.9 mg ethiny... | ||
Medical condition: Contraception | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FI (Completed) ES (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000027-14 | Sponsor Protocol Number: T-19-11318v19 | Start Date*: 2018-08-20 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment Chronic Active Antibody Mediated Rejection in Renal Transplantation | |||||||||||||
Medical condition: Chronic active antibody mediated rejection of renal transplants | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002825-52 | Sponsor Protocol Number: CRAD001A2401T | Start Date*: 2014-04-03 | |||||||||||
Sponsor Name:Medizinische Hochschule Hannover | |||||||||||||
Full Title: Single-center, open-label, single-arm Phase IIa study in kidney transplant patients with acute T-cell-mediated rejection in renal transplant according to Banff criteria (class IA and IB) without (s... | |||||||||||||
Medical condition: Acute cellular rejection after kidney transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002985-15 | Sponsor Protocol Number: MOR202C205 | Start Date*: 2020-10-12 | |||||||||||
Sponsor Name:MorphoSys AG | |||||||||||||
Full Title: A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (N... | |||||||||||||
Medical condition: Anti-PLA2R antibody positive membranous nephropathy (aMN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002678-11 | Sponsor Protocol Number: ICO-13-001 | Start Date*: 2018-06-07 |
Sponsor Name:Institut Català d’Oncologia | ||
Full Title: An open label biomarker pilot study of the antitumoral acrivity of denosumab in the pre-operative setting of early breast cancer | ||
Medical condition: early breast cancer | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2010-018714-73 | Sponsor Protocol Number: GE-067-010 CPR | Start Date*: 2010-04-26 | |||||||||||
Sponsor Name:GE Healthcare Ltd. and its Affiliates | |||||||||||||
Full Title: A Principal, Open-Label, Single Center Study to Validate the Detection of Cerebral Cortical Amyloid with Flutemetamol (18F) Injection in Subjects Previously Biopsied | |||||||||||||
Medical condition: Patients who have been biopsied during an intracranial procedure due to suspected Normal Pressure Hydrocephalus (NPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004694-41 | Sponsor Protocol Number: PRX302-2-08 | Start Date*: 2017-02-03 | |||||||||||
Sponsor Name:Sophiris Bio Corp. 1258 Prospect Street La Jolla, CA 92037 USA | |||||||||||||
Full Title: A Multi-Centre, Open Label, Phase IIb Study, Evaluating the Safety, Tolerability and Efficacy of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically... | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018715-15 | Sponsor Protocol Number: GE-067-011 | Start Date*: 2010-05-12 | |||||||||||
Sponsor Name:GE Healthcare Ltd. and its Affiliates | |||||||||||||
Full Title: A principal, prospective, open-label biopsy study to validate detection of cerebral cortical amyloid with Flutemetamol (18F) Injection in NPH subjects | |||||||||||||
Medical condition: Subjects who are scheduled for intracranial pressure measurement or intracranial shunt placement due to suspected Normal Pressure Hydrocephalus (NPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000138-11 | Sponsor Protocol Number: PIPF-006 | Start Date*: 2006-05-23 |
Sponsor Name:InterMune, Inc. | ||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiophatic Pulmonary Fibrosis | ||
Medical condition: Idiophatic Pulmonary Fibrosis (IPF) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) DE (Completed) BE (Completed) CZ (Prematurely Ended) ES (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
